[Testing for the safety, reactogenicity and antigenic properties of a live thermostable mumps vaccine made from the Leningrad-3 strain].
A live mumps vaccine (LMV) from strain Leningrad-3 with a new stabilizer LS-18 was tested for reactogenicity and antigenic potency. Examinations of vaccinated children for vaccination reactions showed its complete areactogenicity and safety. LMV induced synthesis of virus-neutralizing antibodies in 78-82% of the vaccinees. Determinations of the dynamics, intensity and duration of circulation of specific antihemagglutinating, antineuraminidase and virus-neutralizing antibodies demonstrated marked antigenic potency of the LMV and established production of earliest specific antineuraminidase antibodies in 75% of the vaccinees. EIA was found to be the most sensitive test.